Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Clin Lung Cancer. 2016 Jun 27;18(1):5–12. doi: 10.1016/j.cllc.2016.06.007

Figure 3.

Figure 3

NRG/Alliance 1306. NRG/Alliance 1306 Aims to Demonstrate Utility of Targeted Therapy in EGFR- or ALK-Mutant Unresectable NSCLC Before Definitive Concurrent Chemotherapy and Radiation With Either Weekly Carboplatin–Paclitaxel or 2 Cycles of Split-Dose Cisplatin With Etoposide (EP 50/50)

Abbreviation: NSCLC = non–small-cell lung cancer.